Drugs / Carboprost
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT03390010 Comparator | Dec 2017 → Feb 2018 | — | Aljazeera Hospital | Completed | No outcome recorded |
| — | NCT06285409 Comparator | Apr 2024 → Dec 2026 expected | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Recruiting | No outcome recorded |
| — | NCT01869556 Comparator | Jun 2013 → Jul 2019 | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Completed | No outcome recorded |
| — | NCT00989027 Comparator | Jun 2007 → Aug 2013 | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Carboprost | “medical prophylaxis against postpartum atony and postpartum hemorage by giving misoprostol plus syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost” NCT03390010 ↗ |
| Route | Intramuscular | “Carboprost 0.25mg IM” NCT01869556 ↗ |